|
|
|
|
|
|
Sponsored by: |
Dana-Farber Cancer Institute |
Information provided by: | Dana-Farber Cancer Institute |
ClinicalTrials.gov Identifier: | NCT00165451 |
This study will use a combination of four oral drugs (thalidomide, cyclophosphamide, etoposide and celecoxib) to treat patients with relapsed or progressive cancer. These drugs are expected to target the blood vessels that supply the tumors with what they need to grow.
Condition | Intervention | Phase |
Neoplasms |
Drug: Thalidomide Drug: Celecoxib Drug: Etoposide Drug: Cyclophosphamide |
Phase II |
MedlinePlus related topics: | Cancer |
Drug Information available for: | Cyclophosphamide Etoposide Thalidomide Etoposide phosphate Celecoxib 4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide |
Study Type: | Interventional |
Study Design: | Diagnostic, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Anti-Angiogenic Chemotherapy: A Phase II Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer |
Enrollment: | 20 |
Study Start Date: | June 2001 |
Study Completion Date: | October 2006 |
Primary Completion Date: | October 2006 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | up to 21 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Massachusetts | |||||
Dana-Farber Cancer Institute | |||||
Boston, Massachusetts, United States, 02115 |
Dana-Farber Cancer Institute |
Principal Investigator: | Mark W. Kieran, MD, PhD | Dana-Farber Cancer Institute |
Responsible Party: | Dana-Farber Cancer Institute ( Mark Kieran ) |
Study ID Numbers: | 01-046 |
First Received: | September 9, 2005 |
Last Updated: | December 21, 2007 |
ClinicalTrials.gov Identifier: | NCT00165451 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|